The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Quinine     (5-ethenyl-1- azabicyclo[2.2.2]oct-7-yl)- (6...

Synonyms: Chinine, Conchinin, quinidine, Conquinine, Quniacridine, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of quinidine


Psychiatry related information on quinidine


High impact information on quinidine


Chemical compound and disease context of quinidine


Biological context of quinidine


Anatomical context of quinidine


Associations of quinidine with other chemical compounds


Gene context of quinidine

  • By contrast, the CYP2D6-selective inhibitor quinidine did not affect either microsomal activity, while anti-CYP2A antibodies had only a modest inhibitory effect [32].
  • BACKGROUND: Quinidine is eliminated mainly by CYP3A4-mediated metabolism [33].
  • The quinidine resistance phenotype was confirmed for different yeast strains and growth media, including a prototrophic strain, and YIL121w was named the QDR2 gene [34].
  • Sulphaphenazole (CYP2C9), furafylline (CYP1A2) and quinidine and paroxetine (CYP2D6) gave only little inhibition (IC50 > 60 microM) [35].
  • Overexpression of the yeast genes CIN5 (a member of the family of bZIP transcription factors), STII (a Hsp90 cochaperone), and YOR273c (a member of the major facilitator superfamily of transmembrane transporters) conferred 3.9-, 7.0-, and 4.3-fold resistance to quinidine, respectively, over that of control yeast [36].

Analytical, diagnostic and therapeutic context of quinidine


  1. Quinidine leukopenia and thrombocytopenia with a drug-dependent leukoagglutinin. Castro, O., Nash, I. N. Engl. J. Med. (1977) [Pubmed]
  2. Availability of intravenous quinidine for falciparum malaria. Rosenthal, P.J., Petersen, C., Geertsma, F.R., Kohl, S. N. Engl. J. Med. (1996) [Pubmed]
  3. Treatment of severe malaria in the United States with a continuous infusion of quinidine gluconate and exchange transfusion. Miller, K.D., Greenberg, A.E., Campbell, C.C. N. Engl. J. Med. (1989) [Pubmed]
  4. Current concepts about the treatment of selected poisonings: nitrite, cyanide, sulfide, barium, and quinidine. Smith, R.P., Gosselin, R.E. Annu. Rev. Pharmacol. Toxicol. (1976) [Pubmed]
  5. Interaction between quinidine and digoxin. Leahey, E.B., Reiffel, J.A., Drusin, R.E., Heissenbuttel, R.H., Lovejoy, W.P., Bigger, J.T. JAMA (1978) [Pubmed]
  6. Quinidine dementia. Gilbert, G.J. JAMA (1977) [Pubmed]
  7. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Kharasch, E.D., Hoffer, C., Whittington, D., Sheffels, P. Clin. Pharmacol. Ther. (2003) [Pubmed]
  8. Pharmacokinetics of quinidine in male patients. A population analysis. Verme, C.N., Ludden, T.M., Clementi, W.A., Harris, S.C. Clinical pharmacokinetics. (1992) [Pubmed]
  9. The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers. Wilder-Smith, C.H., Hufschmid, E., Thormann, W. British journal of clinical pharmacology. (1998) [Pubmed]
  10. Quinidine-induced organic mental disorders. Billig, N., Buongiorno, P. Journal of the American Geriatrics Society. (1985) [Pubmed]
  11. Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. Phillips, R.E., Warrell, D.A., White, N.J., Looareesuwan, S., Karbwang, J. N. Engl. J. Med. (1985) [Pubmed]
  12. Digoxin-quinidine interaction Pharmacokinetic evaluation. Hager, W.D., Fenster, P., Mayersohn, M., Perrier, D., Graves, P., Marcus, F.I., Goldman, S. N. Engl. J. Med. (1979) [Pubmed]
  13. The use of in vitro technics to study drug-induced pancytopenia. Kelton, J.G., Huang, A.T., Mold, N., Logue, G., Rosse, W.F. N. Engl. J. Med. (1979) [Pubmed]
  14. Skeletal-muscle damage from quinidine. Yagiela, J.A., Benoit, P.W. N. Engl. J. Med. (1979) [Pubmed]
  15. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. Makkar, R.R., Fromm, B.S., Steinman, R.T., Meissner, M.D., Lehmann, M.H. JAMA (1993) [Pubmed]
  16. Mechanism of the cardiotoxic actions of terfenadine. Woosley, R.L., Chen, Y., Freiman, J.P., Gillis, R.A. JAMA (1993) [Pubmed]
  17. MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. Kanamaru, H., Kakehi, Y., Yoshida, O., Nakanishi, S., Pastan, I., Gottesman, M.M. J. Natl. Cancer Inst. (1989) [Pubmed]
  18. High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand. Looareesuwan, S., White, N.J., Chittamas, S., Bunnag, D., Harinasuta, T. Lancet (1987) [Pubmed]
  19. Procainamide, quinidine, and lupus erythematosus. Amadio, P., Cummings, D.M., Dashow, L. Ann. Intern. Med. (1985) [Pubmed]
  20. Digoxin pharmacokinetics after quinidine. Straub, K.D., Doherty, J.E. JAMA (1981) [Pubmed]
  21. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. Edeki, T.I., He, H., Wood, A.J. JAMA (1995) [Pubmed]
  22. Digitoxin-quinidine interaction: pharmacokinetic evaluation. Fenster, P.E., Powell, J.R., Graves, P.E., Conrad, K.A., Hager, W.D., Goldman, S., Marcus, F.I. Ann. Intern. Med. (1980) [Pubmed]
  23. Altered therapeutic range for quinidine after myocardial infarction and cardiac surgery. Garfinkel, D., Mamelok, R.D., Blaschke, T.F. Ann. Intern. Med. (1987) [Pubmed]
  24. Effects of flecainide and quinidine on human atrial action potentials. Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues. Wang, Z.G., Pelletier, L.C., Talajic, M., Nattel, S. Circulation (1990) [Pubmed]
  25. Direct quantification of apparent binding indices from quinidine-induced in vivo conduction delay in canine myocardium. Haugland, F.N., Johnson, S.B., Packer, D.L. J. Clin. Invest. (1994) [Pubmed]
  26. Characterization of concentration- and use-dependent effects of quinidine from conduction delay and declining conduction velocity in canine Purkinje fibers. Packer, D.L., Grant, A.O., Strauss, H.C., Starmer, C.F. J. Clin. Invest. (1989) [Pubmed]
  27. Effect of quinidine on the digoxin receptor in vitro. Ball, W.J., Tse-Eng, D., Wallick, E.T., Bilezikian, J.P., Schwartz, A., Butler, V.P. J. Clin. Invest. (1981) [Pubmed]
  28. Comparison of flecainide with quinidine for suppression of chronic stable ventricular ectopic depolarizations. A double-blind randomized study in ambulatory outpatients. Salerno, D.M., Hodges, M., Granrud, G., Sharkey, P. Ann. Intern. Med. (1983) [Pubmed]
  29. Drug-induced thrombocytopenia: a systematic review of published case reports. George, J.N., Raskob, G.E., Shah, S.R., Rizvi, M.A., Hamilton, S.A., Osborne, S., Vondracek, T. Ann. Intern. Med. (1998) [Pubmed]
  30. Preeminence of the left stellate ganglion in the long Q-T syndrome. Crampton, R. Circulation (1979) [Pubmed]
  31. Test of a model of antiarrhythmic drug action. Effects of quinidine and lidocaine on myocardial conduction. Hondeghem, L., Katzung, B.G. Circulation (1980) [Pubmed]
  32. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Chang, T.K., Weber, G.F., Crespi, C.L., Waxman, D.J. Cancer Res. (1993) [Pubmed]
  33. Itraconazole increases plasma concentrations of quinidine. Kaukonen, K.M., Olkkola, K.T., Neuvonen, P.J. Clin. Pharmacol. Ther. (1997) [Pubmed]
  34. Saccharomyces cerevisiae multidrug transporter Qdr2p (Yil121wp): localization and function as a quinidine resistance determinant. Vargas, R.C., Tenreiro, S., Teixeira, M.C., Fernandes, A.R., Sá-Correia, I. Antimicrob. Agents Chemother. (2004) [Pubmed]
  35. In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol. Pan, L.P., De Vriendt, C., Belpaire, F.M. Pharmacogenetics (1998) [Pubmed]
  36. Identification of Saccharomyces cerevisiae genes conferring resistance to quinoline ring-containing antimalarial drugs. Delling, U., Raymond, M., Schurr, E. Antimicrob. Agents Chemother. (1998) [Pubmed]
  37. Interaction of quinidine with anticonvulsant drugs. Data, J.L., Wilkinson, G.R., Nies, A.S. N. Engl. J. Med. (1976) [Pubmed]
  38. The electrophysiologic effects of quinidine in the transplanted human heart. Mason, J.W., Winkle, R.A., Rider, A.K., Stinson, E.B., Harrison, D.C. J. Clin. Invest. (1977) [Pubmed]
  39. Absence of the platelet receptor for drug-dependent antibodies in the Bernard-Soulier syndrome. Kunicki, T.J., Johnson, M.M., Aster, R.H. J. Clin. Invest. (1978) [Pubmed]
  40. Quinidine in falciparum malaria. White, N.J., Looareesuwan, S., Warrell, D.A., Chongsuphajaisiddhi, T., Bunnag, D., Harinasuta, T. Lancet (1981) [Pubmed]
  41. Drug purpura due to surreptitious quinidine intake. Reid, D.M., Shulman, N.R. Ann. Intern. Med. (1988) [Pubmed]
WikiGenes - Universities